MedWell AI Touts 280% Growth Amid High-Stakes Health Tech Pivot

CLEARWATER, Fla. – February 23, 2026 – MedWell Ai, Inc. (OTCQB:MWAI) announced striking financial results for its second fiscal quarter of 2025, reporting a revenue surge of over 280% and projecting full-year revenues to surpass $2.2 million. The numbers, released after market close, paint a picture of rapid growth, which the company attributes to a strategic pivot into an AI-driven healthcare and wellness portfolio. However, a deeper look into its public filings reveals a more complex narrative, one of a company navigating significant financial pressures while making a high-stakes bet on some of the most dynamic and controversial sectors of the modern health market.

A Tale of Two Financials

On the surface, MedWell AI's latest financial report is a story of impressive progress. The company posted revenues of $548,315 for the quarter ending December 31, 2025, a dramatic increase from the $142,861 reported in the same period a year prior. For the six-month period, revenues climbed by more than 700% to $1,075,806. This top-line growth was accompanied by improvements in operational efficiency. MedWell AI successfully reduced its net loss for the quarter to $266,221 from $315,096 in the previous year and trimmed its general and administrative expenses by nearly 38%.

Yet, this optimistic picture is juxtaposed with stark warnings contained within the company's own SEC filings. The documents reveal a company facing “serious liquidity pressure.” Management has included a “going concern” notice, a formal disclosure indicating “substantial doubt about its ability to continue” without securing new debt or equity financing. As of December 31, 2025, MedWell AI held just $137,503 in cash against a staggering $7.67 million in current liabilities, creating a working capital deficit of over $7.5 million. The company's accumulated deficit has ballooned to nearly $90 million, and it carries a $500,000 note that remains in default. This financial precarity underscores the high-risk nature of its aggressive growth strategy.

The AI-Fueled Transformation

MedWell AI's current identity is the result of a profound corporate reinvention. The company was formerly known as Integrated Ventures, Inc., a firm focused on the volatile digital asset mining industry. Following regulatory hurdles and a strategic review, the company shed its former operations and re-emerged with a new name and a new mission: to build an “AI-driven healthcare, pharmaceutical and biological wellness portfolio.”

This strategic shift has been swift and decisive. The revenue growth highlighted in the latest report is not from its legacy businesses but from entirely new streams, primarily product sales from its B2B pharmaceutical procurement arm, MedWell USA, and new rental income. This division is at the heart of the company's new model.

Steve Rubakh, CEO of MedWell Ai, Inc., commented on the transition in the company's press release. “MWAI is a newly formed entity... operating in AI-driven pharma/healthcare/wellness category,” he stated. “Q2 financial results reflect significant top-line progress for a fast growing small cap company, driven by its B2B pharma procurement arm, MedWell USA, which focuses on high-demand in-office use, wellness products, like compounded GLP-1 agonists for weight management.”

Riding the GLP-1 Wave

The engine behind MedWell AI’s recent revenue surge is its focus on compounded GLP-1 agonists. These drugs, part of a class that includes blockbuster brands like Ozempic and Wegovy, have seen unprecedented global demand for their effectiveness in weight management and diabetes treatment. This demand has led to persistent shortages and high costs for the branded versions, creating a lucrative, if precarious, market for compounded alternatives.

Compounding pharmacies create customized medications, and in the case of GLP-1s, they have stepped in to fill the supply gap. MedWell USA operates as a B2B procurement platform, facilitating the supply of these compounded drugs to healthcare providers. While this strategy directly addresses a massive market need, it is not without significant risk. The U.S. Food and Drug Administration (FDA) has issued public warnings regarding compounded GLP-1s. The agency emphasizes that these versions are not FDA-approved and do not undergo the same rigorous testing for safety, quality, and efficacy as their branded counterparts. The FDA has specifically cautioned against compounds made from “semaglutide salts,” which are different from the active ingredient in the approved drugs and have not been evaluated for safety. By operating in this space, MedWell AI is capitalizing on a powerful trend but also exposing itself to considerable regulatory scrutiny and potential safety concerns inherent to the compounded drug market.

Charting the Future with Telemedicine

Looking ahead, MedWell AI is betting on further expansion into the digital health space with the planned launch of its 24/7 telemedicine platform, telemd.ai. While details are still emerging, the platform represents a crucial next step in the company's strategy to build an integrated health and wellness ecosystem. Given the company's focus, telemd.ai is expected to leverage artificial intelligence to enhance virtual care, potentially offering services from personalized health recommendations to more efficient patient triage.

In the crowded telemedicine market, dominated by established players like Teladoc and Amwell, differentiation will be key. MedWell AI's potential advantage may lie in creating a seamless link between its virtual care platform and its pharmaceutical supply chain, offering patients a one-stop-shop for consultation and access to treatments like the GLP-1 agonists it distributes. The success of telemd.ai will depend on its ability to offer a unique value proposition and navigate the complex technical and regulatory landscape of virtual healthcare.

As MedWell AI continues to execute its aggressive growth strategy, its journey serves as a compelling case study of a small-cap company leveraging major market trends. The path forward will likely depend on its ability to successfully launch its new telemedicine platform while carefully navigating the significant financial pressures and regulatory scrutiny inherent in its chosen market.